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ASBACKGROUND & AIMS: Sustained activation of the cytosolic
calcium concentration induces injury to pancreatic acinar cells
and necrosis. The calcium release–activated calcium modulator
ORAI1 is the most abundant Ca2þ entry channel in pancreatic
acinar cells; it sustains calcium overload in mice exposed to
toxins that induce pancreatitis. We investigated the roles of
ORAI1 in pancreatic acinar cell injury and the development of
acute pancreatitis in mice. METHODS: Mouse and human
acinar cells, as well as HEK 293 cells transfected to express
human ORAI1 with human stromal interaction molecule 1,
were hyperstimulated or incubated with human bile acid,
thapsigargin, or cyclopiazonic acid to induce calcium entry.
GSK-7975A or CM_128 were added to some cells, which were
analyzed by confocal and video microscopy and patch clamp
recordings. Acute pancreatitis was induced in C57BL/6J mice
by ductal injection of taurolithocholic acid 3-sulfate or intra-
venous’ administration of cerulein or ethanol and palmitoleic
acid. Some mice then were given GSK-7975A or CM_128,
which inhibit ORAI1, at different time points to assess local
and systemic effects. RESULTS: GSK-7975A and CM_128
each separately inhibited toxin-induced activation of ORAI1
and/or activation of Ca2þ currents after Ca2þ release, in a
concentration-dependent manner, in mouse and human
pancreatic acinar cells (inhibition >90% of the levels observed
in control cells). The ORAI1 inhibitors also prevented activation
of the necrotic cell death pathway in mouse and human
pancreatic acinar cells. GSK-7975A and CM_128 each inhibited
all local and systemic features of acute pancreatitis in all 3
models, in dose- and time-dependent manners. The agents were
signiﬁcantly more effective, in a range of parameters, when
given at 1 vs 6 hours after induction of pancreatitis.
CONCLUSIONS: Cytosolic calcium overload, mediated via
ORAI1, contributes to the pathogenesis of acute pancreatitis.
ORAI1 inhibitors might be developed for the treatment of
patients with pancreatitis.Ca2D release-activated Ca2D currents; IL, interleukin; MPO, myeloperox-
idase; PI, propidium iodide; SOCE, store-operated calcium entry; STIM,
stromal interaction molecule; TLCS, taurolithocholate acid sulfate.
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2þStration ([Ca ]C) is a critical trigger for pancreatic
acinar cell injury and necrosis, which depends on store-
operated calcium entry (SOCE).1–4 ORAI1 is the principal
SOCE channel in the pancreatic acinar cell,5 the opening of
which is coordinated by stromal interaction molecule
(STIM)1 and STIM2, after decreases in endoplasmic reticu-
lum calcium store concentrations.3,5–7 GSK-7975A and
CM_128 were developed independently by GlaxoSmithKline
(Stevenage, United Kingdom)3,7,8 and CalciMedica (La Jolla,
CA), respectively, to block ORAI1 channels, although only
CM_128 continues toward clinical development. GSK-7975A
inhibits SOCE induced by thapsigargin in isolated murine
pancreatic acinar cells over the range of 1–50 mmol/L (half-
maximal inhibitory concentration [IC50], w3.4 mmol/L),
3
inhibits endocytic vacuole formation9 and reduces necrosis
induced by toxins that cause acute pancreatitis.3,9 CM_128 is
a new molecular entity. ORAI1 inhibition could inhibit SOCE
and necrosis in human pancreatic acinar cells and amelio-
rate acute pancreatitis.
Genetic knockout of the transient receptor potential ca-
nonical 3 channel,10 a nonselective cation channel regulated
in part by STIM1 via transient receptor potential canonical
1,11 resulted in an approximately 50% reduction of in vivo
serum amylase increase and edema formation induced by 4
injections of cerulein.10 These experiments supported some
role for SOCE in acute pancreatitis, but in a single mild
model with few parameters of response.
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tory effects of GSK-7975A and CM_128 on SOCE and ne-
crosis in murine and human pancreatic acinar cells induced
by taurolithocholic acid 3-sulfate (TLCS)2,12 or cholecysto-
kinin (CCK) 8.1,10 The effects of CM_128 on ORAI1 were
substantiated by examination of its effect on Ca2þ release-
activated Ca2þ currents (ICRAC)
3,6,7 in ORAI1/STIM1-
transfected HEK 293 cells.7 Our in vitro work informed
in vivo pharmacokinetic analysis. GSK-7975A was given at
selected doses after induction of acute pancreatitis (AP)
with TLCS (TLCS-AP),13 7 injections of cerulein (CER-AP)14
or ethanol and palmitoleic acid (FAEE-AP).15 Because GSK-
7975A markedly reduced all parameters of pathobiologic
response in a dose-dependent manner, a high dose of GSK-
7975A and separately CM_128 was begun at 2 different time
points after disease induction to determine the effect of
early vs late drug administration. Drug administration that
was begun 1 hour after disease induction was highly
effective in reducing parameters of pathobiologic response,
signiﬁcantly more so than when begun 6 hours after disease
induction, in all models. These data provide thorough pre-
clinical validation for ORAI channel inhibition as a potential
early treatment for acute pancreatitis.
Materials and Methods
Human Specimen Sampling
Human pancreas was sampled and cells were isolated as
described.16 The time from sampling to the start of cell isola-
tion was fewer than 10 minutes.
Cell Culture and Transfection
HEK 293 cells were cultured and transfected as described.7
HEK 293 cells stably transfected with complementary DNAs
encoding human ORAI1 and STIM1 were used in patch-clamp
recording.
Animals
CD-1 and C57BL/6J mice were from Charles River UK, Ltd
(Margate, Kent, UK). Pancreatic acinar cells were isolated from
CD-1 mice as described.1,3,12,15 For in vivo experiments, 10-
week-old male C57BL/6J mice (25 g) were used.
Confocal Fluorescence Microscopy and
Video Imaging
Isolated pancreatic acinar cells were imaged using a Till
Photonics System (Munich, Germany) to assess [Ca2þ]C with
Fura-2 (5 mmol/L; excitation, 340 and 380 nm; emission, >490
nm; ratio of ﬂuorescence recorded from excitation, 340 and 380
nm) and using LSM710 systems (Carl Zeiss, Jena GmbH) to assess
necrotic cell death pathway activation with propidium iodide
(PI) (1 mmol/L; excitation, 488 nm; emission, 630–693 nm).
Necrotic Cell Death Pathway Activation
Measurement
Cells were treated with GSK-7975A or CM_128 together
with TLCS (500 mmol/L) for 30 minutes, gently shaking at 1000
rpm at room temperature. After washing, cells were stainedwith PI and Hoechst 33342, distributed into 96-well glass
bottom plates (150 mL/well), and imaged using LSM710 sys-
tems. Hoechst 33342 (50 mg/mL; excitation, 364 nm; emission,
405–450 nm) was used to stain nuclei and count the total
number of cells. PI was used to assess plasma membrane
rupture: the total number of cells showing PI uptake was
counted in 3 or more wells and in 12 or more random ﬁelds of
each differently treated group of each isolate to provide a
percentage, averaged across ﬁelds, as the mean ± SEM ﬁeld
percentage PI uptake with 3 or more isolates per group, except
where stated.Patch-Clamp Current Recording
The whole-cell conﬁguration was used to record ICRAC from
hORAI1/hSTIM1 HEK 293 cells.7 Patch pipettes were pulled
from borosilicate glass capillaries (Sutter Instruments) with a
resistance of 2–5 MU when ﬁlled with an extracellular solution
of 120 mmol/L NaCl; 10 mmol/L TEA-Cl; 10 mmol/L HEPES;
10 or 0 mmol/L CaCl2; 2 or 12 mmol/L MgCl2, and 10 mmol/L
glucose, pH 7.2. ICRAC was activated by passive depletion of
intracellular Ca2þ stores using the intracellular solution of 105
mmol/L Cs-glutamate; 10 mmol/L HEPES; 20 mmol/L
1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid; 8
mmol/L MgCl2, pH 7.2. Patched cells were exposed to Ca
2þ-free
buffer to establish stable baseline (for 5 min), then 10 mmol/L
CaCl2 to develop ICRAC (for 10 min), and then CM_128 (0.001,
0.01, 0.1, and 1 mmol/L for 10 min). External recording saline
with no Ca2þ then was perfused for 2 minutes to determine the
background current in the absence of ICRAC. Whole-cell currents
were sampled at 10 KHz and ﬁltered at 2 KHz (Multiclamp
700B ampliﬁer and PClamp software; Axon Instruments). The
voltage clamp protocol included a cycle of steps to 0 mV (for
10 ms to evaluate zero current), then -100 mV (for 10 ms to
measure ICRAC), and a ramp from -100 mV to þ100 mV over
50 ms for I-V relationship followed by step to þ50 mV (for
10 ms to estimate leak current). The voltage between sweeps
was þ30 mV (for 12 s). Whole-cell capacitive compensation
was used. Data analysis was performed using Clampﬁt soft-
ware. ICRAC was measured at -100 mV and current was
measured at approximately 6 minutes and was used as the
baseline control. The current measured after a 10-minute
application of test compound was normalized to the baseline
current (expressed as the percentage of control). The current
measured in zero Ca2þ buffer was used to subtract the back-
ground leak current. Data points were ﬁtted by nonlinear
regression analysis with variable slope (SigmaPlot software) to
determine the IC50 and Hill slope. The IC50 was taken as the
point on the nonlinear regression halfway between the
extrapolated baseline (control) and maximum inhibition pro-
duced by the compound.Experimental Acute Pancreatitis
TLCS-AP was induced by retrograde pancreatic ductal in-
jection with 3 mmol/L TLCS (5 mL/min over 10 minutes by
infusion pump)13; humane killing was 6 or 24 hours later. CER-
AP was induced by 7 hourly intraperitoneal cerulein injections
(50 mg/kg)14; humane killing was 12 hours after the ﬁrst.
FAEE-AP was induced by 2 hourly intraperitoneal injections of
150 mg/kg palmitoleic acid and 1.35 g/kg ethanol15; humane
killing was 6 or 24 hours later. GSK-6288B, the prodrug of
August 2015 ORAI1 Inhibition in Acute Pancreatitis 483GSK-7975A, was administered by minipump; CM_128 was
administered by intraperitoneal injection (6 mice/group).Enzyme Activity and Interleukin 6 Measurement
Trypsin activity was measured as described17 in homoge-
nized tissue (Boc-Gln-Ala-Arg-MCA substrate; excitation, 380
nm; emission, 440 nm). Responses without treatment were
normalized to 100 with SEM to compare different doses of
either drug at different time points across models. Serum
amylase was determined by a Roche Analyzer (Roche); inter-
leukin (IL)6 was determined by enzyme-linked immunosorbent
assay (R&D Systems).Myeloperoxidase Activity
Myeloperoxidase (MPO) activity was determined as
described.18 Pancreatic or lung tissue was homogenized,
resuspended in 100 mmol/L phosphate buffer (pH 5.4) con-
taining 0.5% hexadecyltrimethyl ammonium bromide, 10
mmol/L EDTA and protease inhibitors, freeze-thawed 3 times,
sonicated for 30 seconds, and centrifuged for 15 minutes at
16,000  g. MPO activity was measured in supernatants
(3,3,5,5-tetramethylbenzidine substrate with 0.01% H2O2).
Absorbance was measured at 655 nm and MPO was calculated
as the difference between absorbance at 0 and 3 minutes.Histology
Pancreatic tissue was ﬁxed in 10% formalin, embedded in
parafﬁn, and stained (H&E). Evaluation was performed on 10
random ﬁelds (200) by 2 blinded independent investigators
grading (scale, 0–3) edema, inﬂammatory cell inﬁltration, and
acinar necrosis, calculating the means ± SEM (6 mice/group).BA
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CCK-8 was from American Peptide; ﬂuorescent dyes were
from Molecular Probes; Boc-Gln-Ala-Arg-MCA was from the
Peptide Institute (Osaka, Japan); protease inhibitors were from
Roche GmbH (Mannheim, Germany); IL6 quantikine enzyme-
linked immunosorbent assay kit was from R&D Systems; and
other reagents were from Sigma (Dorset, United Kingdom). 2,6-
diﬂuoro-N-(1-(4-hydroxy-2-(triﬂuoromethyl)benzyl)-1H-pyr-
azol-3-yl)benzamide (GSK-7975A) and pro-drug GSK-6288B
were a gift from GlaxoSmithKline. CM_128 was a gift from
CalciMedica. ALZET osmotic mini-pumps (2001D) were from
Charles River UK, Ltd.Statistical Analysis
Data are presented as means ± SEM. Comparisons were
performed by the 2-tailed Student t test or chi-squared test, and
P values less than .05 were considered signiﬁcant.Study Approval
Human pancreatic samples were obtained with informed
consent as approved by the Liverpool Adult Local Research
Ethics Committee (ref: 03/12/242/A). All animal studies were
ethically reviewed and conducted according to UK Animals
(Scientiﬁc Procedures) Act of 1986, approved by the UK Home
Ofﬁce (PPL 40/3320, renewed as 70/8109).Results
Effects of GSK-7975A and CM_128 on Human
Pancreatic Acinar Cells
Potential translational applications of SOCE inhibition as
a treatment for clinical acute pancreatitis were evaluated by
examination of the effects of GSK-7975A or CM_128 on
isolated human pancreatic acinar cells.16 Thapsigargin was
used in zero external Ca2þ to empty Ca2þ stores, stimulate
STIM-mediated Orai pore formation, and permit SOCE by
the re-introduction of external Ca2þ. GSK-7975A (10–50
mmol/L) inhibited SOCE in these cells (Figure 1A and B).
CM_128 also was found to inhibit SOCE in human pancreatic
acinar cells at lower concentrations (Figure 1C). Both GSK-
7975A (30 mmol/L) and CM_128 (1 mmol/L) inhibited
necrotic cell death pathway activation in these cells
(Figure 1D). To verify that CM_128 inhibits human ORAI1,
HEK 293 cells transfected with ORAI1/STIM17 were
patched in zero extracellular Ca2þ to measure ICRAC in
response to extracellular addition of 10 mmol/L Ca2þ, and
the effect of a range of concentrations of CM_128 tested.
CM_128 was found to inhibit ICRAC in a direct concentration-
dependent manner, with IC50 at approximately 0.1 mmol/L
and no loss of effect at high concentrations (10 mmol/L)
(Figure 1E and F). These ﬁndings were conﬁrmed over the
same concentration range with FLIPR technology (data not
shown).
Effects of GSK-7975A on Murine Pancreatic
Acinar Cells
Isolated murine pancreatic acinar cells maintained in 5
mmol/L external Ca2þ were perfused with TLCS (500 mmol/
L) or supramaximal CCK (1 nmol/L) to induce sustained
increases of [Ca2þ]C dependent on SOCE.
1,3,6,10 Once a stable
plateau in [Ca2þ]C had formed, a range of ﬁxed concentra-
tions (0–100 mmol/L) of GSK-7975A were added. Increasing
concentrations of GSK-7975A decreased the [Ca2þ]C plateau
progressively and increasingly rapidly (Figure 2A–D). With
TLCS, suppression of [Ca2þ]C toward the initial baseline
approached 80% using 30 mmol/L GSK-7975A; with CCK,
more than 95% using 15 mmol/L GSK-7975A, an effect also
seen when cells were maintained in 1.8 mmol/L external
Ca2þ (Supplementary Figure 1A). At 100 mmol/L GSK-
7975A, but not at 50 mmol/L GSK-7975A, there was a loss
of effect through an unknown mechanism (Supplementary
Figure 1B–E). Necrotic cell death pathway activation was
reduced markedly in murine pancreatic acinar cells by GSK-
7975A (Figure 2E).
Effects of CM_128 on Murine Pancreatic
Acinar Cells
To determine the effect of CM_128 on SOCE into isolated
murine pancreatic acinar cells, thapsigargin was used to
empty Ca2þ stores and initiate STIM-mediated ORAI pore
formation, while maintaining cells in zero external Ca2þ
until Ca2þ was re-introduced to enable SOCE.1,3 Application
of this protocol showed that CM_128 reduced SOCE mark-
edly, at a lower dose than that of GSK-7975A (1 mmol/L)
Figure 1.GSK-7975A and CM_128 inhibit CRAC entry (Fura-2 340:380 normalized at 1200 or 2000 s) and necrosis (PI uptake)
in human pancreatic acinar cells and CM_128 concentration-dependently inhibits ICRAC in hORAI1/hSTIM1 HEK 293 cells. (A)
Typical trace showing the inhibitory effect of GSK-7975A (50 mmol/L) on thapsigargin-induced Ca2þ inﬂux. (B) Mean (±SEM)
[Ca2þ]C at 1200 and 1400 s from thapsigargin and thapsigargin plus GSK-7975A traces, showing a marked reduction with
GSK-7975A (20 cells/group; *P < .001; thapsigargin vs thapsigargin plus GSK-7975A at 1400 s). (C) Changes in human
pancreatic acinar [Ca2þ]C induced by thapsigargin (Fura-2 340:380 normalized at 2000 s), showing the inhibitory effect of 1
mmol/L CM_128. (D) GSK-7975A and CM_128 protected isolated human pancreatic acinar cells from necrotic cell death
pathway activation induced by TLCS (500 mmol/L) (mean ± SEM; 3 experiments/group for GSK-7975A; *P < .05, TLCS vs
TLCS plus GSK-7975A and 1 experiment/group [4 wells and 16 high-power ﬁelds each; total. 172 control cells, 97 TLCS, 110
TLCS, and CM_128] for CM_128; *P < .05, TLCS vs TLCS plus CM_128). (E) Typical trace showing ICRAC current in response
to Ca2þ-depletion protocol with 1 mmol/L CM_128 in hORAI1/hSTIM1 HEK 293 cells. (F) Concentration-dependent inhibitory
effects of CM_128 on ICRAC current.
484 Wen et al Gastroenterology Vol. 149, No. 2
BASIC
AND
TRANSLATIONAL
PANCREAS(Figure 3A and B); this same dose also was effective in
signiﬁcantly reducing necrotic cell death pathway activation
by TLCS in these cells (Figure 3C). To conﬁrm the effect of
CM_128 on SOCE and to determine dose-dependency,cyclopiazonic acid was used to empty Ca2þ stores within
murine pancreatic acinar cells10 (maintained in zero
external Ca2þ) to stimulate STIM-mediated ORAI opening.
Upon reintroduction of external Ca2þ (1.8 mmol/L), the rate
Figure 2.GSK-7975A
concentration-dependently
inhibits CRAC entry (Fura-2
340:380 normalized at
700 s) and necrosis (PI up-
take). Changes in mouse
pancreatic acinar [Ca2þ]C
induced by (A) TLCS (500
mmol/L) and (B) CCK (1
nmol/L) showing effects of
GSK-7975A from 700 s,
expanded. (C and D) Mean
(±SEM) [Ca2þ]C at 700,
1200, and 2000 s from
panels A and B, showing
progressive reduction with
increasing GSK-7975A
(19 cells/group; *P <
.001, toxin vs toxin plus
GSK-7975A at 1200 s; †P<
.001 at 2000 s). (E) GSK-
7975A protected isolated
murine pancreatic acinar
cells from necrotic cell
death pathway activation
induced by TLCS (500
mmol/L) (mean ± SEM,
normalized to TLCS at 100;
3 experiments/group;
*P < .001, control vs TLCS;
†P < .001, TLCS vs TLCS
plus GSK-7975A).
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portionality, with the IC50 at approximately 0.7 mmol/L and
no loss of effect at high concentrations (10 mmol/L)
(Figure 3D and E).
Effects of GSK-7975A on Experimental
Acute Pancreatitis
To ensure consistent delivery of GSK-7975A in vivo we
tested subcutaneous minipump administration of GSK-
7975A against a background of CER-AP. Because of the
modest aqueous solubility of GSK-7975A, we used a phos-
phate prodrug (GSK-6288B) that is cleaved rapidly in vivo
to liberate GSK-7975A. Blood and pancreatic levels of GSK-
7975A reached a steady state within 4 hours at all doses
tested (Supplementary Figure 2). GSK-7975A at 28 (low)
and 110 (high) mg/kg/h achieved steady-state blood con-
centrations of approximately 4.3 mmol/L and approximately
13.3 mmol/L, and pancreatic concentrations of approxi-
mately 8.9 mmol/L and approximately 49.3 mmol/L,
respectively, with no detectable prodrug at all doses and
time points.
GSK-7975A was tested in 3 clinically representative
mouse models of acute pancreatitis. TLCS-AP, which is
representative of acute biliary pancreatitis from ampullary
gallstone obstruction, was induced by pancreatic ductalinfusion of TLCS13 and minipumps inserted 30 minutes
later. At both doses GSK-7975A signiﬁcantly reduced in-
creases in serum amylase, IL6, and pancreatic MPO levels;
lung MPO was reduced signiﬁcantly by low dose only
(Figure 4). There were consistent reductions in pancreatic
edema, inﬂammatory cell inﬁltration, and acinar cell ne-
crosis, with a marked reduction in overall histopathology
score in the GSK-7975A–treated groups; inﬂammatory cell
inﬁltration and histopathology score were reduced signiﬁ-
cantly more by the higher dose (Figure 5).
CER-AP is the most widely used model that is repre-
sentative of acute pancreatitis induced by hyperstimula-
tion,14 such as from anticholinesterase insecticides or Tityus
species scorpion stings.19 In CER-AP, minipumps were
inserted with the third of 7 cerulein injections. At both
doses GSK-7975A signiﬁcantly reduced the increases in
serum amylase, pancreatic trypsin, and MPO levels, with the
low dose resulting in signiﬁcant reductions in IL6 and lung
MPO levels (Figure 4). Pancreatic histopathology showed a
trend toward a reduction in the low-dose group; at the high
dose, there were signiﬁcant marked reductions in all mea-
sures of pancreatic histopathology, approaching control
levels (Figure 5).
FAEE-AP parallels acute alcoholic pancreatitis through
in vivo formation of toxic ethanol metabolites.15 Minipumps
Figure 3. CM_128 concentration-dependently inhibits CRAC entry and necrosis (PI uptake). (A) Changes in mouse pancreatic
acinar [Ca2þ]C induced by thapsigargin (Fura-2 340:380 normalized at 2000 s), showing effect of 1 mmol/L CM_128. (B) Mean
(±SEM) [Ca2þ]C at 2000 and 3000 s from panel A, showing a marked reduction with 1 mmol/L CM_128 (62 cells/group; *P <
.001, thapsigargin vs thapsigargin plus CM_128 at 3000 s). (C) CM_128 protected isolated murine pancreatic acinar cells from
necrotic cell death pathway activation induced by TLCS (500 mmol/L) (mean ± SEM; 3 experiments/group; *P < .001, TLCS
vs control; †P < .05, TLCS vs TLCS plus CM_128). (D) Concentration-dependent inhibitory effects of CM_128 on cyclopiazonic
acid–induced Ca2þ inﬂux, showing a progressive reduction of the initial rate of Ca2þ entry and plateau with increasing
CM_128, with complete inhibition of Ca2þ entry at 10 mmol/L (17 cells/group). (E) Concentration-dependent inhibitory effects
of CM_128 on the initial rate of Ca2þ entry.
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intraperitoneal injections of ethanol and palmitoleic acid.
GSK-7975A reduced the increases in all parameters, with
pancreatic and lung MPO levels signiﬁcantly reduced at the
low dose; serum amylase level, IL6 level, pancreatic trypsin
level, and histopathology were reduced signiﬁcantly at the
high dose (Figures 4 and 5). There were signiﬁcantly greater
reductions in edema, inﬂammation, and the overall histo-
pathology score at the high dose, with levels of necrosis
approaching control levels (Figure 5). In all models, low-
dose GSK-7975A was generally as effective as the high
dose in reducing IL6, which contributes to lung injury and
lethality,20 and MPO. These data are consistent with the
lower IC50 of GSK-7975A on ORAI channel SOCE in leuko-
cytes (w1 mmol/L for T lymphocytes)7,8 than in pancreatic
acinar cells (3.4 mmol/L).3Effects of CM_128 on Experimental
Acute Pancreatitis
Preliminary in vivo experiments indicated that CM_128
has a signiﬁcantly longer half-life than GSK-7975A, and is
suitable for intraperitoneal dosing every 12 hours to achieve
sustained blood levels with more than 99% bound (free
fraction in murine plasma, 0.33%; when added to human
plasma, 0.16%). Because our work with high-dose GSK-
7975A showed greater efﬁcacy in vivo than with low-doseGSK-7975A, and in vitro data obtained with CM_128
did not suggest loss of efﬁcacy at high concentrations
(10 mmol/L), we administered 20 mg/kg CM_128 every 12
hours to test the efﬁcacy of this agent in TLCS-AP and FAEE-
AP. We also determined the relative efﬁcacy of CM_128
administered either 1 or 6 hours after induction of either
model of acute pancreatitis. CM_128 begun 1 hour after
disease induction signiﬁcantly reduced all parameters of
both TLCS-AP and FAEE-AP, including all local and systemic
biochemical, immunologic, and histopathologic measures
(Figures 6 and 7). CM_128 begun 6 hours after disease in-
duction was less effective across a broad range of parame-
ters (Figures 6 and 7), signiﬁcantly so for IL6 (TLCS-AP),
pancreatic MPO (FAEE-AP), and lung MPO (TLCS-AP),
although signiﬁcant reductions still were seen in amylase
(TLCS-AP and FAEE-AP), lung MPO (TLCS-AP), edema
(TLCS-AP and FAEE-AP), inﬂammation (FAEE-AP), necrosis
(FAEE-AP), and total histopathology score (FAEE-AP). To
determine the extent to which disease was established at 6
hours after disease induction, and the effect of CM_128
begun at that time, all parameters were assessed at 6 hours
and compared with values at 24 hours. These data showed
that by 24 hours there was no signiﬁcant improvement of
parameters as measured at 6 hours as a result of CM_128
administration begun at 6 hours (Supplementary Figures 3
and 4), conﬁrming delay in therapy to be disadvanta-
geous; although CM_128 appeared to prevent these
Figure 4.GSK-7975A
markedly reduces all
biochemical responses of
TLCS-AP, CER-AP, and
FAEE-AP. All models resul-
ted in substantial increases
of (A) serum amylase, (B)
IL6, (C) pancreatic trypsin
activity, (D) pancreatic
activity, and (E) lung MPO
activity. Subcutaneous os-
motic minipump adminis-
tration of GSK-7975A given
as prodrug GSK-6288B at
low (L) or high (H) doses
signiﬁcantly reduced all
parameters, with a more
marked reduction of serum
amylase and IL6, pancre-
atic trypsin at the high dose
(mean ± SEM 6 mice/
group; *P< .05, control vs 3
models; †P < .05 TLCS-AP
vs TLCS-AP plus GSK-
7975A; ‡P < .05, CER-AP
vs CER-AP plus GSK-
7975A; and §P < .05,
FAEE-AP vs FAEE-AP plus
GSK-7975A).
August 2015 ORAI1 Inhibition in Acute Pancreatitis 487
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
PA
NC
RE
ASparameters from increasing. To further explore the effect of
delay in dosing, the effect of high-dose GSK-7975A on dis-
ease responses also was tested at 1 and 6 hours after in-
duction. Similar to CM_128, GSK-7975A begun 6 hours after
disease induction was less effective across a broad range of
parameters (Supplementary Figures 5 and 6), signiﬁcantly
so for amylase (TLCS-AP and FAEE-AP), IL6 (TLCS-AP),
edema (TLCS-AP and FAEE-AP), inﬂammatory inﬁltrate
(TLCS-AP), and total histopathology score (TLCS-AP and
FAEE-AP).Discussion
We found GSK-7975A and the new molecular entity
CM_128 to inhibit toxin-induced SOCE into murine and hu-
man pancreatic acinar cells in a concentration-dependent
manner, exceeding more than 90% block of relative con-
trol values in some protocols. We also found both GSK-
7975A and CM_128 to reduce signiﬁcantly the necrotic
cell death pathway activation in murine and human
pancreatic acinar cells exposed to TLCS, which inducesacute pancreatitis in vivo.13,14 Although effects of GSK-
7975A have been described on thapsigargin- and palmito-
leic acid ethyl ester–induced murine pancreatic acinar
SOCE,3 our study found GSK-7975A to have a similarly
critical effect on TLCS- and CCK-induced murine pancreatic
acinar SOCE, as well as thapsigargin-induced human
pancreatic acinar SOCE and TLCS-induced human pancreatic
acinar necrotic cell death pathway activation. CM_128
showed a higher potency (IC50 w0.1 mmol/L from ORAI1/
STIM1-transfected HEK 293 cell patch-clamp data), and
unlike GSK-7975A, no loss of efﬁcacy at high doses.
Comprehensive in vivo evaluation using 3 diverse, clinically
representative models of acute pancreatitis14 with prior
pharmacokinetic assessment showed the validity of SOCE
inhibition as a therapeutic approach. Thus, administration of
either compound within 1 hour after disease induction was
markedly effective across a representative range of local
and systemic biochemical, immunologic, and histologic dis-
ease responses.
Our novel human data support the potential applicability
of SOCE inhibition as a treatment for clinical acute
Figure 5.GSK-7975A markedly reduces pancreatic histopathology in TLCS-AP, CER-AP, and FAEE-AP. All models resulted in
substantial increases in (A) edema, (B) inﬂammation, (C) necrosis, and (D) total histology score. Subcutaneous osmotic
minipump administration of GSK-7975A given as prodrug GSK-6288B at low (L) or high (H) doses markedly reduced
pancreatic damage, with more marked reduction at high dose (mean ± SEM 6 mice/group; *P < .05 control vs 3 models;
†P < .05, TLCS-AP vs TLCS-AP plus GSK-7975A; ‡P < .05, CER-AP vs CER-AP plus GSK-7975A; and §P < .05, FAEE-AP vs
FAEE-AP plus GSK-7975A). (E) Representative images showing normal pancreatic histology, typical histopathology from all 3
models, and typical histopathology from all 3 models after treatment with GSK-7975A at low (L) or high (H) doses (H&E; scale
bar: 50 mm).
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promptly, shown here to result in complete block of human
ORAI1 by CM_128. Although an action on other ORAI
channels cannot be excluded and could be desirable, ORAI1is the primary channel for SOCE into pancreatic acinar
cells,3,5 blocked by both compounds. ORAI channels also
contribute to inﬂammatory cell responses, including
neutrophil migration and activation21; inhibition of innate
Figure 6. CM_128 mark-
edly reduces all biochem-
ical responses of TLCS-AP
and FAEE-AP. Two
models resulted in sub-
stantial increases of (A)
serum amylase, (B) IL6, (C)
pancreatic trypsin activity,
(D) pancreatic activity, and
(E) lung MPO activity.
Intraperitoneal administra-
tion of CM_128 at 20 mg/
kg given at 1 hour after
disease induction (early)
and 6 hours after (late)
signiﬁcantly reduced all
parameters, with more
marked reduction of IL6,
pancreatic activity, and
lung MPO activity when
CM_128 was administered
early (mean ± SEM 6
mice/group; *P < .05,
control vs 2 models; †P <
.05 TLCS-AP vs TLCS-AP
plus CM_128; ‡P < .05,
FAEE-AP vs FAEE-AP plus
CM_128; and §P < .05,
CM_128 early vs late).
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experimental acute pancreatitis,22 thus there may be a
contribution here from ORAI inhibition of immune cells.
Nevertheless, although knockout of ORAI1/STIM1 SOCE
inhibits neutrophil functions, it does not prevent all func-
tions,21 so the primary contribution of ORAI blockade in our
experiments is likely to have been in the pancreas.
Furthermore, because SOCE inhibition for clinical acute
pancreatitis would necessarily be short term, inhibition of
the adaptive immune system21 also would be short term.
ORAI blockade has less effect on other cell types in which
ORAI channels have a less prominent role, such as electri-
cally excitable cells in which other ion channels (eg,
nonselective cation channels) have a larger role in Ca2þ
entry.23 Nonselective cation channels, however, permit
limited SOCE into pancreatic acinar cells3,10 that could
sustain essential Ca2þ entry.23 Without such Ca2þ entry,continued activation of the plasma membrane Ca2þ-adeno-
sine triphosphatase pump upon secretagogue- or toxin-
mediated release of Ca2þ from intracellular stores could
deplete these stores to deleterious levels, inducing or
exacerbating endoplasmic reticulum stress.24
Measurement of blood and tissue levels of GSK-7975A
after induction of experimental acute pancreatitis estab-
lished an appropriate dosing regimen (110 mg/kg/h via
minipump) for maximum effect, at a steady state of 10–15
mmol/L in blood and approximately 50 mmol/L in the
pancreas, with less than 10% free GSK-7975A. Our cell data
indicated that at 50 mmol/L, GSK-7975A had no loss of ef-
fect, and the concentration of free compound in vivo was
signiﬁcantly lower. At this dose, however, GSK-7975A was
highly effective in reducing all measures of disease response
in 3 clinically representative models of acute pancreatitis
(TLCS-AP, CER-AP, and FAEE-AP), and more so than at a
Figure 7. CM_128 markedly reduces pancreatic histopathology in TLCS-AP and FAEE-AP. Both models resulted in substantial
increases in (A) edema, (B) inﬂammation, (C) necrosis, and (D) total histology score. Intraperitoneal administration of CM_128 at
20 mg/kg given at 1 hour after disease induction (early) and 6 hours after (late) signiﬁcantly reduced all parameters, with a more
marked reduction when CM_128 was administered early (mean ± SEM 6 mice/group; *P < .05, control vs 2 models; †P < .05
TLCS-AP vs TLCS-AP plus CM_128; ‡P < .05, FAEE-AP vs FAEE-AP plus CM_128; and §P < .05, CM_128 early vs late). (E)
Representative images showing normal pancreatic histology, typical histopathology from 2 models, and typical histopathology
from 2 models after treatment with CM_128 early and late after disease induction (H&E; scale bar: 50 mm).
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than GSK-7975A but higher levels of plasma and tissue
binding, was tested at 20 mg/kg given every 12 hours via
intraperitoneal injection in TLCS-AP and FAEE-AP, repre-
sentative of gallstone and alcoholic acute pancreatitis,14,15
the most common forms of the disease.4 This resulted in
CM_128 levels greater than 7 mmol/L in blood and
approximately 50 mmol/L in the pancreas 11 hours after the
last dose, levels that were highly effective in reducing all
disease parameters. These data provide robust conﬁrmation
of the hypothesis that cytosolic Ca2þ overload is a critical
trigger of acute pancreatitis.25
Both compounds were administered after disease in-
duction to model treatment of clinical acute pancreatitis,
but a delay in administration of either compound to 6
hours after disease induction resulted in diminished efﬁ-
cacy, dependent on the end point measured and the model
used. Although biological time courses including that of
acute pancreatitis are longer in human beings than in
mice,4,14,26 with pancreatic necrosis typically detected
within days rather than hours,4,27 human pancreatic acinar
necrotic cell death pathway activation may begin in
clinical acute pancreatitis at an early stage after disease
onset, shown here in mouse models within 6 hours of
onset. Door-to-needle times of less than 60 minutes are
established guidelines for patients with acute myocardial
infarction (30 min)28 and acute ischemic stroke (60
min),29 making every second count, with national and in-
ternational quality-improvement initiatives underway to-
ward fully achieving these.30 Although pancreatic necrosis
has a less rapid time course and is not the result of major
arterial occlusion,4 the translational implication of our
work is that door-to-needle time is an important issue in
administration of any treatment for acute pancreatitis that
targets the pathogenesis of pancreatic injury, which drives
the disease. Previously, clinical trials of treatments for
acute pancreatitis “enriched” recruitment with patients
predicted to have severe disease (often with recruitment
up to 72 h after admission),4,31 which delays the initiation
of therapy. Furthermore, the expansion of disease cate-
gories from the original Atlanta Classiﬁcation (mild and
severe)32 into the revised Atlanta (mild, moderate, and
severe)33 and Determinants-Based (mild, moderate, se-
vere, and critical)34 classiﬁcation, further complicates pa-
tient selection from among these potentially overlapping
subgroups. To minimize door-to-needle time, a quicker
and more accurate approach to the selection of patients is
required for trials of any therapy, such as that offered here
with ORAI inhibition by CM_128, a novel molecular entity
currently undergoing preclinical toxicologic evaluation
before phase I trials.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.04.015.References
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Supplementary Materials and Methods
Measurements of GSK-7975A and CM_128
In Vivo
Sampling of GSK-7975A was at 1, 2, 4, 10, and 22 hours
after osmotic minipump insertion from 3 mice/time point.
Immediately after humane killing, blood was collected into a
heparinized tube, diluted 1:1 with sterile water, and the
pancreas was removed and homogenized in 2 mL Covaris
tubes containing ceramic beads. Standards and study sam-
ples (50 mL from blood and 100 mL from pancreas) were
extracted by protein precipitation and centrifuged. Super-
natants were dried under heated nitrogen (40C). Levels of
GSK-7975A and GSK-6288B were determined by LC-MS/MS
(API4000 with Jasco X-LC and Ascentis express C18 col-
umn), as were levels of CM_128 in plasma and pancreas
(Varian 500-MS with Varian 212 LC and Phenomenex C8
column), sampling from 3 mice at the same time point when
drug efﬁcacy was assessed.
Protein Binding of GSK-7975A and CM_128
The protein binding of GSK-7975A in the blood and
pancreas was determined at 1 mg/mL using a dialysis Teﬂon
block (HTDialysis, LLC, Gales Ferry, CT) with dialysis
membrane strips and a rapid equilibrium dialysis device
(Thermo Scientiﬁc), respectively. The protein binding of
CM_128 in plasma (from Bioreclamation, Inc, Westbury, NY)
was determined at 30 mmol/L or 50 mmol/L by equilibrium
dialysis using a high-throughput dialysis Teﬂon block
(HTDialysis, LLC) and dialysis membrane strips. Blood was
collected into a heparin precoated tube and diluted 1:1 with
phosphate-buffered saline (pH 7.4). Pancreas was homoge-
nized in 500 mL phosphate-buffered saline, diluted 1:10.
Blood, pancreas, homogenate, and plasma were dialyzed
against phosphate-buffered saline in a buffer chamber,
shaking gently at 37C for 5 hours (blood), 4 hours
(pancreas homogenate), and overnight (plasma). After
equilibrium, samples from both the sample chamber and the
buffer chamber of the rapid equilibrium dialysis plate were
collected in a matrix-match manner and analyzed by liquid
chromatography–mass spectrometry (AP14000; Applied
Biosystems; or Varian 500-MS with Varian 212 LC and
Phenomenex C8 column). Experiments were performed in
triplicate. The percentage of GSK-7975A bound was calcu-
lated by the following equation: % bound¼ ([GSK-7975A]a -
[GSK-7975A]b)/[GSK-7975A]a 100%, where [GSK-7975A]a
was the concentration of GSK-7975A in the sample chamber
and [GSK-7975A]b was the concentration of GSK-7975A in
the buffer chamber. The same equation was applied to
calculate CM_128 binding.
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Supplementary Figure 1.GSK-7975A inhibits CRAC entry (Fura-2 340:380 normalized at 700 s). (A) Changes in mouse
pancreatic acinar [Ca2þ]C induced by CCK (1 nmol/L) with external physiological [Ca
2þ] (1.8 mmol/L) applied, showing the
effect of 15 mmol/L GSK-7975A from 700 seconds, expanded (79 cells/group). Changes in mouse pancreatic acinar [Ca2þ]C
induced by (B) TLCS (500 mmol/L) and (C) CCK (1 nmol/L), showing effects of 50 and 100 mmol/L GSK-7975A from 700
seconds, expanded. (D and E) Mean (±SEM) [Ca2þ]C at 700, 1200, and 2000 seconds from panels B and C, showing a marked
reduction with 50 mmol/L GSK-7975A, but not 100 mmol/L GSK-7975A (27 cells/group; *P < .001, toxin vs toxin plus GSK-
7975A at 1200 s; †P < .001, at 2000 s).
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Supplementary Figure 2.GSK-7975A given as prodrug GSK-6288B administered by a subcutaneous osmotic minipump can
be delivered consistently to each mouse and maintained throughout the experimental period. There was no detectable GSK-
6288B in the blood or pancreas, suggesting complete conversion into GSK-7975A. (A) Blood and pancreas levels of GSK-
7975A after administration of 2 mg/kg/h GSK-6288B showing a steady state 4 hours after minipump implantation, when the
mean concentrations in blood and pancreas were approximately 0.4 and approximately 0.6 mmol/L respectively. (B) Blood and
pancreas levels of GSK-7975A at the (lower) dose of 28 mg/kg/h GSK 6288B (L) reached a steady state 1 hour after minipump
implantation, when the mean concentrations in blood and pancreas were approximately 5 and approximately 10 mmol/L,
respectively. (C) Blood and pancreas levels of GSK-7975A at the (higher) dose of 110 mg/kg/h GSK-6288B (H) reached a steady
state 4 hours after minipump implantation, when the mean concentrations in blood and pancreas were approximately 15 and
approximately 50 mmol/L, respectively. (D) Mean (±SEM) plasma and pancreas levels of CM_128 at 20 mg/kg sampling at the
time point when drug efﬁcacy was assessed, were approximately 10 and approximately 50 mmol/L, respectively.
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Supplementary Figure 3. CM_128 administered from 6 hours after disease induction (late) markedly reduced biochemical
responses in TLCS-AP and FAEE-AP. Two models at 6 and 24 hours resulted in substantial increase of (A) serum amylase, (B)
IL6, (C) pancreatic trypsin activity, (D) pancreatic activity, and (E) lung MPO activity, with more marked increase of IL6 and lung
MPO activity at 6 hours, but of pancreatic trypsin and MPO activity at 24 hours. Intraperitoneal administration of CM_128 at
20 mg/kg late signiﬁcantly reduced all parameters from levels at 6 hours (mean ± SEM 6 mice/group; *P < .05, control vs 2
models at 6 h; †P < .05 2 models at 6 vs 24 h; ‡P< .05, TLCS-AP at 6 h vs TLCS-AP plus CM_128; §P < .05, FAEE-AP at 6 h vs
FAEE-AP plus CM_128).
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Supplementary Figure 4. CM_128 administered from 6 hours after disease induction (late) markedly reduced pancreatic
histopathology in TLCS-AP and FAEE-AP. Two models at 6 and 24 hours resulted in substantially progressive increases in (A)
edema, (B) inﬂammation, (C) necrosis, and (D) total histology score, with more marked increase of all scores at 24 hours.
Intraperitoneal administration of CM_128 at 20 mg/kg from 6 hours after disease induction signiﬁcantly reduced edema, but
not inﬂammation, necrosis, or total histology scores at 6 hours (mean ± SEM 6 mice/group; *P < .05, control vs 2 models at 6
hours; †P < .05 2 models at 6 vs 24 hours; ‡P < .05, TLCS-AP at 6 h vs TLCS-AP plus CM_128; §P < .05, FAEE-AP at 6 h vs
FAEE-AP plus CM_128). (E) Representative images showing normal pancreatic histology, typical histopathology from 2
models at 6 and 24 hours, and typical histopathology from 2 models after treatment with CM_128 administered late after
disease induction (H&E; scale bar: 50 mm).
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Supplementary Figure 5.GSK-7975A administered from 6 hours after disease induction (late) less effectively reduced
biochemical responses of TLCS-AP and FAEE-AP. Two models resulted in substantial increases of (A) serum amylase, (B) IL6,
(C) pancreatic trypsin activity, (D) pancreatic activity, and (E) lung MPO activity. Subcutaneous osmotic minipump adminis-
tration of GSK-7975A given as prodrug GSK-6288B at high dose administered from a late time point was less protective than
when given early (mean ± SEM 6 mice/group; *P < .05, control vs 2 models; †P < .05 TLCS-AP vs TLCS-AP plus GSK-
7975A; ‡P < .05, FAEE-AP vs FAEE-AP plus GSK-7975A; and §P < .05, GSK-7975A early vs GSK-7975A late).
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Supplementary Figure 6.GSK-7975A administered from 6 hours after disease induction (late) less effectively reduced
pancreatic histopathology in TLCS-AP and FAEE-AP. Two models resulted in substantial increases in (A) edema, (B)
inﬂammation, (C) necrosis, and (D) total histology score. Subcutaneous osmotic minipump administration of GSK-7975A given
as prodrug GSK-6288B at high dose administered from a late time point was less effective that when begun early (mean ±
SEM 6 mice/group; *P < .05, control vs 2 models; †P < .05 TLCS-AP vs TLCS-AP plus GSK-7975A; ‡P < .05, FAEE-AP vs
FAEE-AP plus GSK-7975A, and §P < .05, GSK-7975A early vs GSK-7975A late). (E) Representative images showing normal
pancreatic histology, typical histopathology from 2 models, and typical histopathology from 2 models after treatment with
GSK-7975A administered early and late after disease induction (H&E; scale bar: 50 mm).
August 2015 ORAI1 Inhibition in Acute Pancreatitis 492.e7
